User contributions
Jump to navigation
Jump to search
- 17:31, 14 April 2024 diff hist +328 m Osteosarcoma - null regimens current
- 17:29, 14 April 2024 diff hist +45 m Non-small cell lung cancer, nonsquamous →Maintenance after first-line therapy
- 17:28, 14 April 2024 diff hist +33 m Non-small cell lung cancer, nonsquamous →Consolidation after definitive therapy for inoperable disease
- 17:27, 14 April 2024 diff hist -70 m Non-small cell lung cancer - historical
- 17:25, 14 April 2024 diff hist +74 m Multiple myeloma - historical
- 17:23, 14 April 2024 diff hist +140 m Multiple myeloma, consolidation and maintenance
- 17:21, 14 April 2024 diff hist +9 m Mantle cell lymphoma →Preceding treatment
- 17:20, 14 April 2024 diff hist +26 m Mantle cell lymphoma →Brexucabtagene autoleucel monotherapy {{#subobject:4z3u14|Regimen=1}}
- 17:19, 14 April 2024 diff hist +10 m Low-grade glioma →Regimen variant #3, continuous therapy {{#subobject:3871fe|Variant=1}}
- 17:19, 14 April 2024 diff hist +24 m Light-chain (AL) amyloidosis →Relapsed or refractory
- 17:16, 14 April 2024 diff hist +43 m Glioblastoma →Maintenance after first-line therapy
- 12:49, 14 April 2024 diff hist +44 m Ewing sarcoma
- 12:48, 14 April 2024 diff hist -36 m Acute promyelocytic leukemia
- 12:43, 14 April 2024 diff hist +355 m Diffuse large B-cell lymphoma
- 11:27, 14 April 2024 diff hist +69 m Small cell lung cancer - historical
- 11:09, 14 April 2024 diff hist +1,805 m Paroxysmal nocturnal hemoglobinuria →Iptacopan monotherapy {{#subobject:aa617d |Regimen=1}}
- 10:43, 14 April 2024 diff hist +58 m Paroxysmal nocturnal hemoglobinuria →References
- 10:41, 14 April 2024 diff hist +56 m Drug index →I
- 10:40, 14 April 2024 diff hist -25 m Drug index →I
- 10:40, 14 April 2024 diff hist +125 m Iptacopan (Fabhalta) current
- 10:38, 14 April 2024 diff hist +34 N Iptacopan (LNP-023) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval current Tag: New redirect
- 10:38, 14 April 2024 diff hist 0 m Iptacopan (Fabhalta) Jwarner moved page Iptacopan (LNP-023) to Iptacopan (Fabhalta): FDA approval
- 10:38, 14 April 2024 diff hist +248 m Iptacopan (Fabhalta)
- 10:34, 14 April 2024 diff hist -223 m Pheochromocytoma →Sunitinib monotherapy {{#subobject:ec3261|Regimen=1}}
- 10:33, 14 April 2024 diff hist +2,063 Pheochromocytoma →All lines of therapy
- 15:29, 13 April 2024 diff hist +82 m Follicular lymphoma →Maintenance after subsequent lines of therapy
- 15:27, 13 April 2024 diff hist +55 m Follicular lymphoma →Consolidation after subsequent lines of therapy
- 15:25, 13 April 2024 diff hist +227 m Follicular lymphoma →Maintenance after first-line therapy
- 15:22, 13 April 2024 diff hist +204 m Follicular lymphoma →Consolidation after first-line therapy
- 15:17, 13 April 2024 diff hist +11 m Follicular lymphoma →Observation
- 15:17, 13 April 2024 diff hist +27 m Follicular lymphoma →Radiation therapy {{#subobject:6298df|Regimen=1}}
- 15:14, 13 April 2024 diff hist +10 m Esophageal cancer →Definitive therapy
- 15:13, 13 April 2024 diff hist +11 m Esophageal cancer →Preceding treatment
- 15:12, 13 April 2024 diff hist +1 m Diffuse large B-cell lymphoma →Lenalidomide monotherapy {{#subobject:e4284f|Regimen=1}}
- 15:11, 13 April 2024 diff hist +230 m Diffuse large B-cell lymphoma →Relapsed or refractory, salvage therapy
- 15:06, 13 April 2024 diff hist +61 m Diffuse large B-cell lymphoma
- 15:04, 13 April 2024 diff hist +65 m Diffuse large B-cell lymphoma →Maintenance after upfront therapy
- 15:03, 13 April 2024 diff hist +217 m Diffuse large B-cell lymphoma →Consolidation after upfront therapy
- 15:00, 13 April 2024 diff hist +58 m Diffuse large B-cell lymphoma - null regimens current
- 14:58, 13 April 2024 diff hist +10 m Diffuse large B-cell lymphoma - historical →Consolidation after upfront therapy
- 14:57, 13 April 2024 diff hist +12 m Colorectal cancer →Advanced or metastatic disease, third-line therapy
- 14:56, 13 April 2024 diff hist +33 m Colorectal cancer →Advanced or metastatic disease, second-line therapy
- 14:56, 13 April 2024 diff hist +25 m Colorectal cancer →Advanced or metastatic disease, first-line
- 14:54, 13 April 2024 diff hist +88 m Colorectal cancer →Maintenance after first-line therapy
- 12:54, 13 April 2024 diff hist +77 m CNS lymphoma →Relapsed or refractory, salvage therapy
- 12:54, 13 April 2024 diff hist +285 m CNS lymphoma →Consolidation after upfront therapy
- 12:51, 13 April 2024 diff hist +87 m CNS lymphoma →Upfront therapy, non-randomized or retrospective data
- 12:49, 13 April 2024 diff hist +107 m CNS lymphoma →Upfront therapy, randomized data
- 12:47, 13 April 2024 diff hist +11 m CNS lymphoma →Methotrexate monotherapy {{#subobject:e89965|Regimen=1}}
- 12:47, 13 April 2024 diff hist +20 m CNS lymphoma
- 12:46, 13 April 2024 diff hist +20 m CNS lymphoma - null regimens current
- 11:38, 13 April 2024 diff hist +30 m Pancreatic cancer →Regimen variant #2, q4wk indefinite {{#subobject:fcd708|Variant=1}}
- 11:37, 13 April 2024 diff hist +60 m Pancreatic cancer →Regimen {{#subobject:242770|Variant=1}}
- 11:35, 13 April 2024 diff hist +2,181 Pancreatic cancer →Capecitabine monotherapy {{#subobject:38b5c7|Regimen=1}}
- 00:22, 13 April 2024 diff hist +39 m Classical Hodgkin lymphoma - historical
- 00:20, 13 April 2024 diff hist +79 m Classical Hodgkin lymphoma - null regimens current
- 00:19, 13 April 2024 diff hist +1,517 m Classical Hodgkin lymphoma
- 23:54, 12 April 2024 diff hist +68 m Chronic myeloid leukemia
- 23:53, 12 April 2024 diff hist +13 m Chronic myeloid leukemia →Subsequent treatment
- 23:52, 12 April 2024 diff hist +44 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:6cdc45|Regimen=1}}
- 23:49, 12 April 2024 diff hist +14 m Breast cancer, HER2-positive →Preceding treatment
- 23:47, 12 April 2024 diff hist +241 m Breast cancer, ER-positive
- 23:41, 12 April 2024 diff hist +25 m Bladder cancer →Induction chemoradiotherapy
- 23:40, 12 April 2024 diff hist +27 m B-cell acute lymphoblastic leukemia →Preceding treatment
- 23:38, 12 April 2024 diff hist +10 m Anaplastic glioma →Preceding treatment
- 18:31, 12 April 2024 diff hist +2,514 m Clear cell renal cell carcinoma
- 18:26, 12 April 2024 diff hist +944 m Breast cancer - null regimens →References
- 18:26, 12 April 2024 diff hist +944 m Breast cancer, BRCA-mutated →References
- 18:06, 12 April 2024 diff hist +16 m CARv3-TEAM-E T-cells current
- 18:05, 12 April 2024 diff hist +658 N CARv3-TEAM-E T-cells Created page with "==Mechanism of action== anti-EGFR CAR T-cells ==Preliminary data== ===Glioblastoma=== #'''INCIPIENT:''' Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Ni..."
- 18:03, 12 April 2024 diff hist +26 m Drug index →C
- 18:00, 12 April 2024 diff hist +34 N Category:SPEAR T-cells Created page with "Category:Immune effector cells" current
- 18:00, 12 April 2024 diff hist +26 N Category:Anti-MAGE-A4 SPEAR T-cells Created page with "Category:SPEAR T-cells" current
- 17:59, 12 April 2024 diff hist -35 m Afamitresgene Autoleucel (ADP-A2M4) current
- 17:59, 12 April 2024 diff hist +36 N Category:Liposarcoma medications (investigational) Created page with "Category:Liposarcoma medications" current
- 17:59, 12 April 2024 diff hist +1,888 N Afamitresgene Autoleucel (ADP-A2M4) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afamitresgene-autoleucel NCI Drug Dictionary]: A preparation of autologous h..."
- 17:54, 12 April 2024 diff hist +41 m Drug index →A
- 10:17, 12 April 2024 diff hist +81 m Breast cancer, ER-positive - null regimens current
- 10:15, 12 April 2024 diff hist +8,424 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 10:15, 12 April 2024 diff hist -8,424 m Breast cancer - historical →CAV {{#subobject:90f8d0|Regimen=1}}
- 00:18, 12 April 2024 diff hist +3,422 Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 00:16, 12 April 2024 diff hist +3,428 Non-small cell lung cancer, ALK-positive →Cisplatin & Pemetrexed {{#subobject:b9uc2c|Regimen=1}}
- 00:13, 12 April 2024 diff hist 0 m Non-small cell lung cancer, ALK-positive →Regimen variant #2, 750 mg/day fasting {{#subobject:47c6e4|Variant=1}}
- 00:13, 12 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive
- 00:12, 12 April 2024 diff hist +1,691 m Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:b94ckc|Regimen=1}}
- 17:47, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 17:47, 11 April 2024 diff hist +1,691 Non-small cell lung cancer, ALK-positive →Alectinib monotherapy {{#subobject:bbc3cc|Regimen=1}}
- 15:48, 11 April 2024 diff hist +6 m Non-small cell lung cancer, ALK-positive
- 15:48, 11 April 2024 diff hist +2,021 Non-small cell lung cancer, ALK-positive →Advanced or metastatic disease, ALK inhibitor-naive
- 10:47, 11 April 2024 diff hist +1,029 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 10:45, 11 April 2024 diff hist +977 m Gastric cancer →SOX {{#subobject:ecig8a|Regimen=1}}
- 12:40, 10 April 2024 diff hist -4,351 m Hereditary hemorrhagic telangiectasia
- 12:40, 10 April 2024 diff hist +5,450 N Hereditary hemorrhagic telangiectasia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:38, 10 April 2024 diff hist +265 m Hereditary hemorrhagic telangiectasia
- 12:27, 10 April 2024 diff hist +30 m Sickle cell anemia
- 12:27, 10 April 2024 diff hist +1,575 m Sickle cell anemia - null regimens →Placebo {{#subobject:9149f2|Regimen=1}} current
- 12:25, 10 April 2024 diff hist +7,736 N Sickle cell anemia - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 12:25, 10 April 2024 diff hist -2,018 m Sickle cell anemia
- 12:21, 10 April 2024 diff hist +246 m Sickle cell anemia
- 11:22, 10 April 2024 diff hist +215 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist -4,761 m Smoldering multiple myeloma
- 11:21, 10 April 2024 diff hist +5,684 N Smoldering multiple myeloma - null regimens Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..." current
- 11:19, 10 April 2024 diff hist +255 m Smoldering multiple myeloma
- 11:48, 9 April 2024 diff hist +13 m Vincristine liposomal (Marqibo) →History of changes in FDA indication current
- 11:47, 9 April 2024 diff hist +11 m Tositumomab and I-131 (Bexxar) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:46, 9 April 2024 diff hist +11 m Rucaparib (Rubraca) →History of changes in FDA indication current
- 11:45, 9 April 2024 diff hist +251 m Pembrolizumab (Keytruda) →Small cell lung cancer - WITHDRAWN current
- 11:45, 9 April 2024 diff hist +424 m Pembrolizumab (Keytruda) →Gastric or gastroesophageal junction adenocarcinoma - PARTIALLY WITHDRAWN
- 11:44, 9 April 2024 diff hist +12 m Panobinostat (Farydak) →History of changes in FDA indication current
- 11:43, 9 April 2024 diff hist +14 m Olaratumab (Lartruvo) →History of changes in FDA indication current
- 11:41, 9 April 2024 diff hist +107 m Umbralisib (Ukoniq) →History of changes in FDA indication current
- 11:38, 9 April 2024 diff hist +8 m Ibrutinib (Imbruvica) →History of changes in FDA indication - PARTIALLY WITHDRAWN current
- 11:38, 9 April 2024 diff hist +385 m Ibrutinib (Imbruvica) →History of changes in FDA indication
- 11:36, 9 April 2024 diff hist +308 m Pralsetinib (Gavreto) →History of changes in FDA indication current
- 11:34, 9 April 2024 diff hist +31 N Category:FDA withdrawn in 2024 Created page with "Category:Discontinued drugs" current
- 11:33, 9 April 2024 diff hist +225 m Copanlisib (Aliqopa) current
- 11:30, 9 April 2024 diff hist +10 m Olaparib (Lynparza) →Ovarian cancer - PARTIALLY WITHDRAWN current
- 11:30, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Small cell lung cancer - WITHDRAWN current
- 11:29, 9 April 2024 diff hist +12 m Nivolumab (Opdivo) →Hepatocellular carcinoma - PARTIALLY WITHDRAWN
- 11:29, 9 April 2024 diff hist +13 m Melphalan flufenamide (Pepaxto) →Multiple myeloma - WITHDRAWN current
- 11:23, 9 April 2024 diff hist +21 m Idelalisib (Zydelig) →History of changes in FDA indication current
- 11:23, 9 April 2024 diff hist +12 m Gemtuzumab ozogamicin (Mylotarg) →History of changes in FDA indication current
- 11:22, 9 April 2024 diff hist +12 m Gefitinib (Iressa) →Non-small cell lung cancer - PARTIALLY WITHDRAWN current
- 11:21, 9 April 2024 diff hist -116 m Duvelisib (Copiktra) →History of changes in FDA indication current
- 11:18, 9 April 2024 diff hist +12 m Bevacizumab (Avastin) →Breast cancer - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +24 m Atezolizumab (Tecentriq) →Urothelial carcinoma - WITHDRAWN current
- 11:17, 9 April 2024 diff hist +12 m Atezolizumab (Tecentriq) →Breast cancer, triple negative - WITHDRAWN
- 00:50, 9 April 2024 diff hist +27 m Soft tissue sarcoma
- 00:50, 9 April 2024 diff hist 0 m Soft tissue sarcoma - null regimens current
- 00:49, 9 April 2024 diff hist +23 m Testicular cancer →Consolidation after salvage therapy
- 00:43, 9 April 2024 diff hist +81 m Non-small cell lung cancer →Maintenance after first-line therapy
- 00:42, 9 April 2024 diff hist +277 m Non-small cell lung cancer
- 23:59, 8 April 2024 diff hist +150 m Non-small cell lung cancer - null regimens current
- 22:15, 8 April 2024 diff hist +128 m Anaplastic glioma
- 20:55, 8 April 2024 diff hist +58 m Acute myeloid leukemia →Relapsed or refractory, salvage therapy
- 20:54, 8 April 2024 diff hist +21 m Acute myeloid leukemia →Maintenance after first-line therapy
- 20:53, 8 April 2024 diff hist +405 m Acute myeloid leukemia →Consolidation after upfront therapy
- 20:49, 8 April 2024 diff hist +99 m Acute myeloid leukemia →First-line induction therapy, older or "unfit" patients
- 20:47, 8 April 2024 diff hist +48 m Acute myeloid leukemia →Subsequent induction therapy, standard and older "fit" patients
- 20:47, 8 April 2024 diff hist +375 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 20:40, 8 April 2024 diff hist +30 m Multiple myeloma - null regimens current
- 20:39, 8 April 2024 diff hist +79 m Follicular lymphoma - historical
- 20:36, 8 April 2024 diff hist +128 m Esophageal cancer
- 20:32, 8 April 2024 diff hist +36 m Acute myeloid leukemia, pediatric - historical
- 20:31, 8 April 2024 diff hist +44 m Acute myeloid leukemia, pediatric →Consolidation after salvage therapy current
- 20:30, 8 April 2024 diff hist +14 m Acute myeloid leukemia, pediatric →Relapsed or refractory, salvage therapy
- 20:30, 8 April 2024 diff hist +38 m Acute myeloid leukemia, pediatric →Consolidation after upfront therapy
- 20:29, 8 April 2024 diff hist +43 m Acute myeloid leukemia, pediatric →Upfront induction therapy
- 20:29, 8 April 2024 diff hist +10 m Acute myeloid leukemia, pediatric
- 20:25, 8 April 2024 diff hist +14 m Acute promyelocytic leukemia →Consolidation after salvage therapy
- 20:23, 8 April 2024 diff hist +172 m Acute promyelocytic leukemia →Upfront induction therapy
- 17:50, 8 April 2024 diff hist +14 m Acute myeloid leukemia - null regimens current
- 17:48, 8 April 2024 diff hist +32 m B-cell acute lymphoblastic leukemia, Ph-positive
- 17:46, 8 April 2024 diff hist +10 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive
- 17:45, 8 April 2024 diff hist +34 m B-cell acute lymphoblastic leukemia, pediatric - historical
- 17:45, 8 April 2024 diff hist +28 m B-cell acute lymphoblastic leukemia, pediatric
- 17:42, 8 April 2024 diff hist +116 m B-cell acute lymphoblastic leukemia
- 17:35, 8 April 2024 diff hist +89 m Breast cancer, HER2-positive →Maintenance for metastatic or unresectable disease
- 17:32, 8 April 2024 diff hist 0 m Breast cancer, HER2-positive →Metastatic or unresectable disease, first-line
- 17:31, 8 April 2024 diff hist +57 m Breast cancer, HER2-positive →Adjuvant therapy
- 17:29, 8 April 2024 diff hist +82 m Breast cancer, HER2-positive →Adjuvant therapy, sequential regimens
- 17:23, 8 April 2024 diff hist +93 m Breast cancer, HER2-positive →Neoadjuvant therapy
- 17:19, 8 April 2024 diff hist +150 m Ewing sarcoma
- 17:15, 8 April 2024 diff hist +22 m Melanoma
- 17:14, 8 April 2024 diff hist +11 m Melanoma - null regimens
- 17:13, 8 April 2024 diff hist +36 m Medulloblastoma - historical
- 15:57, 8 April 2024 diff hist +41 m Mantle cell lymphoma →Maintenance after second-line therapy
- 15:56, 8 April 2024 diff hist +8 m Mantle cell lymphoma →Consolidation after second-line therapy
- 15:55, 8 April 2024 diff hist +116 m Mantle cell lymphoma →Maintenance after first-line therapy
- 15:52, 8 April 2024 diff hist +110 m Mantle cell lymphoma →Consolidation after first-line therapy
- 15:50, 8 April 2024 diff hist +186 m Mantle cell lymphoma →First-line therapy, non-randomized or retrospective data
- 15:44, 8 April 2024 diff hist +94 m Mantle cell lymphoma →First-line therapy, randomized data
- 15:43, 8 April 2024 diff hist +11 m Mantle cell lymphoma →First-line therapy, pre-phase
- 15:41, 8 April 2024 diff hist +54 m Multiple myeloma, relapsed-refractory
- 15:39, 8 April 2024 diff hist +9 m Osteosarcoma
- 15:38, 8 April 2024 diff hist 0 m Osteosarcoma - null regimens
- 15:22, 8 April 2024 diff hist 0 m Osteosarcoma - historical
- 14:42, 8 April 2024 diff hist +57 m Rectal cancer →Adjuvant chemotherapy
- 14:40, 8 April 2024 diff hist +213 m Rectal cancer →Neoadjuvant therapy
- 14:36, 8 April 2024 diff hist +36 m Rectal cancer - null regimens current
- 14:28, 8 April 2024 diff hist +205 m Small cell lung cancer →Extensive stage, induction
- 14:24, 8 April 2024 diff hist +126 m Small cell lung cancer →Limited stage, consolidation after upfront therapy
- 14:21, 8 April 2024 diff hist +2 m Small cell lung cancer →Limited stage, definitive chemoradiotherapy
- 14:20, 8 April 2024 diff hist +34 m Small cell lung cancer →Limited stage, induction
- 14:20, 8 April 2024 diff hist +53 m Small cell lung cancer - null regimens current
- 14:15, 8 April 2024 diff hist -41 m Urothelial carcinoma
- 13:23, 8 April 2024 diff hist 0 m T-cell acute lymphoblastic leukemia
- 13:22, 8 April 2024 diff hist +24 m Ovarian cancer - historical →Maintenance after second-line therapy for platinum-sensitive disease
- 13:21, 8 April 2024 diff hist +24 m Ovarian cancer - historical
- 13:20, 8 April 2024 diff hist +11 m Malignant pleural mesothelioma - null regimens current
- 13:19, 8 April 2024 diff hist +11 m Low-grade glioma - null regimens current
- 13:19, 8 April 2024 diff hist +20 m Low-grade glioma
- 13:18, 8 April 2024 diff hist +111 m HIV-associated lymphoma
- 13:16, 8 April 2024 diff hist +4 m Colorectal cancer, RAS wild-type
- 13:14, 8 April 2024 diff hist +22 m Colorectal cancer - null regimens current
- 12:58, 8 April 2024 diff hist +105 m Classical Hodgkin lymphoma, pediatric - historical
- 12:57, 8 April 2024 diff hist +262 m Classical Hodgkin lymphoma, pediatric
- 12:53, 8 April 2024 diff hist +67 m Chronic myeloid leukemia
- 12:19, 8 April 2024 diff hist -131 m Cellular therapy conditioning regimens
- 12:17, 8 April 2024 diff hist -1 m Castleman disease
- 23:23, 7 April 2024 diff hist +17 m Chronic myelomonocytic leukemia →Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}
- 23:23, 7 April 2024 diff hist +1,102 m Myelodysplastic syndrome →Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}
- 23:21, 7 April 2024 diff hist +1,103 m Chronic myelomonocytic leukemia
- 23:15, 7 April 2024 diff hist +750 m Chronic lymphocytic leukemia →References
- 23:14, 7 April 2024 diff hist +1,523 m Chronic lymphocytic leukemia →Bendamustine & Rituximab (BR) {{#subobject:7542a2|Regimen=1}}
- 23:06, 7 April 2024 diff hist +3 m Chronic lymphocytic leukemia →Ibrutinib monotherapy {{#subobject:8c370d|Regimen=1}}
- 22:53, 7 April 2024 diff hist 0 m Multiple myeloma →ASCO/CCO
- 22:52, 7 April 2024 diff hist +259 m Carcinoma of unknown primary →ESMO
- 22:51, 7 April 2024 diff hist +225 m Head and neck cancer →ASCO
- 22:47, 7 April 2024 diff hist 0 m Penile cancer →EAU-ASCO
- 22:10, 7 April 2024 diff hist +261 m Prostate cancer →ASCO
- 22:05, 7 April 2024 diff hist +306 m Ovarian cancer →ASCO
- 22:03, 7 April 2024 diff hist +234 m Ovarian cancer, HRD-positive →ASCO
- 22:02, 7 April 2024 diff hist +196 m Hepatocellular carcinoma →ASCO
- 21:57, 7 April 2024 diff hist +270 m ASCO guidelines →Bone-modifying agents
- 21:54, 7 April 2024 diff hist +1 m Breast cancer, ER-positive →ASCO
- 21:52, 7 April 2024 diff hist +526 m Breast cancer, ER and HER2 co-expressing →ASCO/CAP
- 21:51, 7 April 2024 diff hist +542 m Breast cancer, ER-positive →ASCO
- 13:44, 7 April 2024 diff hist +1,008 m Breast cancer →ASCO/CCO
- 13:38, 7 April 2024 diff hist +2 m Breast cancer →ASCO/CCO
- 13:36, 7 April 2024 diff hist +1,336 m ASCO guidelines →Cancer cachexia
- 13:31, 7 April 2024 diff hist +6 m Breast cancer, HER2-positive →ASCO
- 13:21, 7 April 2024 diff hist +2 m Breast cancer, CNS metastases →ASCO
- 13:20, 7 April 2024 diff hist +1,184 m Breast cancer, ER and HER2 co-expressing →Guidelines
- 13:19, 7 April 2024 diff hist +1,183 m Breast cancer, HER2-positive →ASCO
- 13:14, 7 April 2024 diff hist +493 m Breast cancer, BRCA-mutated →ASCO
- 13:12, 7 April 2024 diff hist +236 m Breast cancer →ASCO/CCO
- 13:09, 7 April 2024 diff hist +321 m Breast cancer, ER-positive →ASCO
- 01:30, 7 April 2024 diff hist -180 m Classical Hodgkin lymphoma, pediatric
- 00:30, 7 April 2024 diff hist +664 m Urothelial carcinoma
- 00:26, 7 April 2024 diff hist +520 m Hepatocellular carcinoma
- 00:25, 7 April 2024 diff hist +520 m Hepatocellular carcinoma - historical
- 11:02, 5 April 2024 diff hist -663 m Non-small cell lung cancer
- 11:01, 5 April 2024 diff hist -284 m Non-small cell lung cancer →Pembrolizumab monotherapy {{#subobject:430dc7|Regimen=1}}
- 21:26, 4 April 2024 diff hist -1 m Diffuse large B-cell lymphoma →R-NIMP {{#subobject:fb6d8|Regimen=1}}
- 12:23, 3 April 2024 diff hist +4 m Ovarian cancer
- 12:21, 3 April 2024 diff hist +4 m Medulloblastoma
- 11:10, 2 April 2024 diff hist +4 m Prostate cancer →Regimen variant #1, 6 cycles {{#subobject:EJCADTdoceV|Variant=1}}
- 00:08, 1 April 2024 diff hist +399 m Pembrolizumab (Keytruda) →MSI-H or dMMR tumors (tissue-agnostic)
- 00:01, 1 April 2024 diff hist +15 m Pembrolizumab (Keytruda) →Small cell lung cancer - WITHDRAWN
- 23:41, 31 March 2024 diff hist +3,631 Cervical cancer →Cisplatin & RT {{#subobject:89c649|Regimen=1}}
- 23:27, 31 March 2024 diff hist +7 m Erdafitinib (Balversa) →History of changes in FDA indication current
- 23:26, 31 March 2024 diff hist +4 m Urothelial carcinoma →Regimen variant #2 {{#subobject:47gh17|Variant=1}}
- 23:22, 31 March 2024 diff hist +76 m Malignant solid neoplasm, NTRK-mutated →References current
- 16:31, 31 March 2024 diff hist +1,808 Chronic myeloid leukemia, pediatric →Dasatinib monotherapy {{#subobject:51eb88|Regimen=1}} current
- 16:27, 31 March 2024 diff hist +1,803 m Chronic myeloid leukemia, pediatric →Imatinib monotherapy [COG AAML0123] {{#subobject:917a16|Regimen=1}}
- 13:37, 31 March 2024 diff hist +41 m Bosutinib (Bosulif) current
- 13:35, 31 March 2024 diff hist +3,312 Pyruvate kinase deficiency
- 13:25, 31 March 2024 diff hist -1,698 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency current
- 10:08, 31 March 2024 diff hist +514 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency